The clinical relevance of <scp>MOG</scp> antibody testing in cerebrospinal fluid-Reference-Cited by-同舟云学术

The clinical relevance of MOG antibody testing in cerebrospinal fluid

Published:2024-07-28 Issue: Volume: Page:
ISSN:2328-9503
Container-title:Annals of Clinical and Translational Neurology
language:en
Short-container-title:Ann Clin Transl Neurol

Author:

Reynolds Molly¹²,Tan Irene³,Nguyen Kristy⁴,Merheb Vera⁴,Lee Fiona X. Z.⁴,Trewin Benjamin P¹⁵^ORCID,Lerch Magdalena¹,Shah Snehal⁶,Wolfe Nigel⁷,Buzzard Katherine⁸,Lechner‐Scott Jeannette⁹¹⁰,Fabis‐Pedrini Marzena¹¹¹²,Fok Anthony¹³¹⁴,John Nevin¹³¹⁴,Kneebone Chris¹⁵,Yiannikas Con¹⁶,Brown David A.¹⁷¹⁸,Kermode Allan G.¹¹¹²,Reddel Stephen²⁵,Dale Russell C.⁵¹⁹²⁰^ORCID,Brilot Fabienne⁴²¹^ORCID,Ramanathan Sudarshini¹²⁵^ORCID,

Affiliation:

1. Translational Neuroimmunology Group, Kids Neuroscience Centre, Faculty of Medicine and Health University of Sydney Sydney Australia

2. Department of Neurology Concord Hospital Sydney Australia

3. Department of Radiology Concord Hospital Sydney Australia

4. Brain Autoimmunity Group Kids Neuroscience Centre, Children's Hospital at Westmead Sydney Australia

5. Sydney Medical School and Brain and Mind Centre, Faculty of Medicine and Health University of Sydney Sydney Australia

6. Department of Neurology, Perth Children's Hospital University of Western Australia Perth Australia

7. Department of Neurology Blacktown Hospital Sydney Australia

8. MS and Neuroimmunology Service, Royal Melbourne Hospital Melbourne Australia

9. Hunter Medical Research Institute, Faculty of Medicine and Public Health University of Newcastle Newcastle Australia

10. Department of Neurology John Hunter Hospital Newcastle Australia

11. The Perron Institute for Neurological and Translational Science University of Western Australia Perth Australia

12. The Centre for Molecular Medicine and Innovative Therapeutics Murdoch University Perth Australia

13. Department of Neuroscience Monash Health Melbourne Australia

14. Department of Medicine, School of Clinical Sciences Monash University Melbourne Australia

15. Department of Neurology, Royal Adelaide Hospital Adelaide Australia

16. Inner West Neurology Burwood Sydney Australia

17. ICPMR and Department of Immunopathology, NSW Health Pathology Westmead Hospital Westmead Sydney Australia

18. Clinical Immunology and Allergy Research Westmead Institute for Medical Research Westmead Sydney Australia

19. Clinical Neuroimmunology Group Kids Neuroscience Centre, Children's Hospital at Westmead Sydney Australia

20. TY Nelson Department of Neurology Children's Hospital at Westmead Sydney Australia

21. School of Medical Science and Brain and Mind Centre, Faculty of Medicine and Health University of Sydney Sydney Australia

Abstract

AbstractMyelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) is diagnosed by serum MOG‐immunoglobulin G (MOG‐IgG) in association with typical demyelination. 111/1127 patients with paired CSF/serum samples were seropositive for MOG‐IgG. Only 7/1016 (0.7%) seronegative patients had CSF‐restricted MOG‐IgG. While 3/7 patients had longitudinally extensive transverse myelitis, four had a confirmed alternate diagnosis (three multiple sclerosis, one CNS vasculitis). In a national referral setting, CSF‐restricted MOG‐IgG had a low sensitivity (2.63%, 95%CI 0.55–7.50%) and low positive predictive value (1.97%, 95%CI 0.45–8.13%). We strongly recommend serum as the preferred diagnostic biospecimen, and urge caution in the interpretation of CSF‐restricted MOG‐IgG in patients without clinico‐radiological features consistent with MOGAD.

Funder

National Health and Medical Research Council

Royal Australasian College of Physicians

Faculty of Medicine and Health, University of Sydney

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/acn3.52163

Reference17 articles.

1. Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination

2. Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF